Krystal Biotech (NASDAQ: KRYS) and ARS Pharmaceuticals (NASDAQ: SPRY) are gaining attention for their groundbreaking commercial therapies. Krystal’s Vyjuvek is the first FDA-approved topical genetic therapy for a rare skin disorder, while ARS’s Neffy is the first non-injectable epinephrine product for anaphylaxis.

Krystal Biotech uses viral vectors to deliver gene therapies for diseases like cystic fibrosis and lung diseases. Their KB707 candidate for non-small cell lung cancer recently received a Regenerative Medicine Advanced Therapy designation from the FDA, expediting its development.

Krystal Biotech expects to report annual sales of $388-389 million for Vyjuvek, with significant revenue growth and potential. ARS Pharmaceuticals is focusing on expanding Neffy’s indications and has seen a rapid uptake in orders, indicating room for growth in the epinephrine market.

ARS Pharma’s Neffy ads drew FDA scrutiny for inaccurately suggesting it eliminates the need for injections in allergic reaction emergencies. The company is trading at $8.81 per share with plans to develop new indications for Neffy and ARS-2 for chronic urticaria.

When considering investing in Krystal Biotech, note that the Motley Fool’s Stock Advisor analysts did not include it in their top 10 stock picks. The potential for high returns in the biotech sector is highlighted, but investors should weigh the risks of single-product companies like Krystal and ARS.

ARS Pharma reported revenues of $51.8 million in 2025, a significant increase from the previous year, and has $288.2 million in cash on hand. With a growing market for epinephrine, ARS has potential for profitability despite its current losses and stock price decline.

Read more at Yahoo Finance: Got $300? 2 Biotech Stocks to Buy and Hold Forever